Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234025 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
NCT01234025 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 113 participants.
The verdict
NCT01234025, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG ISIS EIF4E Rx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234025
The ClinicalTrials.gov registry entry for NCT01234025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01234025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234025 about?
NCT01234025 is a clinical study titled "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)". The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
What is the current status of trial NCT01234025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2010-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01234025?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), ISIS EIF4E Rx (DRUG).
Who is sponsoring clinical trial NCT01234025?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.